Page 583 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 25 Tumors of the Skeletal System 561

265. Walter CU, Dernell WS, LaRue SM, et al.: Curative-intent radia- 283. Kurzman ID, Shi F, Vail DM, et al.: In vitro and in vivo enhance-
tion therapy as a treatment modality for appendicular and axial ment of canine pulmonary alveolar macrophage cytotoxic activ-
osteosarcoma; a preliminary retrospective evaluation of 14 dogs ity against canine osteosarcoma cells, Cancer Biother Radiopharm
VetBooks.ir 266. Chakraborty S, Das T, Sarma HD, et al.: Comparative studies of 284. MacEwen EG, Kurzman ID, Rosenthal RC, et al.: Therapy for osteo-
14:121–128, 1999.
with the disease, Vet Comp Oncol 3:1–7, 2005.
177Lu-EDTMP and 177Lu-DOTMP as potential agents for pal-
liative radiotherapy of bone metastasis, Appl Radiat Isot 66:1196– sarcoma in dogs with intravenous injection of liposome–encapsulated
muramyl tripeptide, J Natl Cancer Inst 81:935–938, 1989.
1205, 2008. 285. Kurzman ID, MacEwen EG, Rosenthal RC, et al.: Adjuvant ther-
267. Zhou JJ, Gonzalez A, Lenox MW, et al.: Dosimetry of a (90) apy for osteosarcoma in dogs; results of randomized clinical trials
Y-hydroxide liquid brachytherapy treatment approach to canine using combined liposome-encapsulated muramyl tripeptide and
osteosarcoma using PET/CT, Appl Radiat Isot 97:193–200, cisplatin, Clin Cancer Res 1:1595–1601, 1995.
2015. 286. Modiano JF, Bellgrau D, Cutter GR, et al.: Inflammation, apop-
268. Khanna C, Prehn J, Hayden D, et al.: A randomized controlled tosis, and necrosis induced by neoadjuvant fas ligand gene therapy
trial of octreotide pamoate long-acting release and carboplatin improves survival of dogs with spontaneous bone cancer, Mol Ther
versus carboplatin alone in dogs with naturally occurring osteo- 20:2234–2243, 2012.
sarcoma; evaluation of insulin-like growth factor suppression and 287. Mason NJ, Gnanandarajah JS, Engiles JB, et al.: Immunotherapy
chemotherapy, Clin Cancer Res 8:2406–2412, 2002. with a HER2-targeting listeria induces HER2-specific immunity
269. Vail DM, Kurzman ID, Glawe PC, et al.: STEALTH liposome- and demonstrates potential therapeutic effects in a phase I trial in
encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant canine osteosarcoma, Clin Cancer Res 22:4380–4390, 2016.
therapy for spontaneously arising osteosarcoma (OSA) in the dog; 288. Polednak AP: Human biology and epidemiology of childhood
a randomized multicenter clinical trial, Cancer Chemoth Pharmacol bone cancers; a review, Hum Biol 57:1–26, 1985.
50:131–136, 2002. 289. London CA, Gardner HL, Mathie T, et al.: Impact of toceranib/
270. Philips B, Powers BE, Dernell WS, et al.: Use of single-agent car- piroxicam/cyclophosphamide maintenance therapy on outcome of
boplatin as adjuvant or neoadjuvant therapy in conjunction with dogs with appendicular osteosarcoma following amputation and
amputation for appendicular osteosarcoma in dogs, J Am Anim carboplatin chemotherapy; a multi-institutional study, PLoS One
Hosp Assoc 45:33–38, 2009. 10:e0124889, 2015.
271. Saam DE, Liptak JM, Stalker MJ, et al.: Predictors of outcome in 290. Alvarez FJ, Kisseberth W, Hosoya K, et al.: Postoperative adjuvant
dogs treated with adjuvant carboplatin for appendicular osteosar- combination therapy with doxorubicin and noncytotoxic suramin
coma; 65 cases (1996-2006), J Am Vet Med Assoc 238:195–206, in dogs with appendicular osteosarcoma, J Am Anim Hosp Assoc
2011. 50:12–18, 2014.
272. Berg J, Weinstein MJ, Springfield DS, et al.: Results of surgery and 291. Downey RJ: Surgical treatment of pulmonary metastases, Surg
doxorubicin chemotherapy in dogs with osteosarcoma, J Am Vet Oncol Clin North Amer 8:341, 1999.
Med Assoc 206:1555–1560, 1995. 292. Liptak JM, Monnet E, Dernell WS, et al.: Pulmonary metastatec-
273. Chun R, Garrett LD, Henry C, et al.: Toxicity and efficacy of cispl- tomy in the management of four dogs with hypertrophic osteopa-
atin and doxorubicin combination chemotherapy for the treatment thy, Vet Comp Oncol 2:1–12, 2004.
of canine osteosarcoma, J Am Anim Hosp Assoc 41:382–387, 2005. 293. Ogilvie GK, Straw RC, Jameson VJ, et al.: Evaluation of single-
274. Chun R, Kurzman ID, Couto CG, et al.: Cisplatin and doxorubi- agent chemotherapy for treatment of clinically evident osteosar-
cin combination chemotherapy for the treatment of canine osteo- coma metastases in dogs; 45 cases (1987-1991uo), J Am Vet Med
sarcoma; a pilot study, J Vet Intern Med 14:495–498, 2000. Assoc 202:304–306, 1993.
275. Bailey D, Erb H, Williams L, et al.: Carboplatin and doxorubi- 294. Poirier VJ, Hershey AE, Burgess KE, et al.: Efficacy and toxicity of
cin combination chemotherapy for the treatment of appendicular paclitaxel (Taxol) for the treatment of canine malignant tumors,
osteosarcoma in the dog, J Vet Intern Med 17:199–205, 2003. J Vet Intern Med 18:219–222, 2004.
276. Kent MS, Strom A, London CA, et al.: Alternating carboplatin and 295. London CA, Hannah AL, Zadovoskaya R, et al.: Phase I dose-esca-
doxorubicin as adjunctive chemotherapy to amputation or limb- lating study of SU11654, a small molecule receptor tyrosine kinase
sparing surgery in the treatment of appendicular osteosarcoma in inhibitor, in dogs with spontaneous malignancies, Clin Cancer Res
dogs, J Vet Intern Med 18:540–544, 2004. 9:2755–2768, 2003.
277. Bacon NJ, Ehrhart NP, Dernell WS, et al.: Use of alternating admin- 296. London C, Mathie T, Stingle N, et al.: Preliminary evidence for
istration of carboplatin and doxorubicin in dogs with microscopic biologic activity of toceranib phosphate (Palladia((R))) in solid
metastases after amputation for appendicular osteosarcoma; 50 cases tumours, Vet Comp Oncol 10:194–205, 2012.
(1999-2006), J Am Vet Med Assoc 232:1504–1510, 2008. 297. Laver T, London CA, Vail DM, et al.: Prospective evaluation of
278. Lane A, Black M, Wyatt K: Toxicity and efficacy of a novel doxoru- toceranib phosphate in metastatic canine osteosarcoma, Vet Comp
bicin and carboplatin chemotherapy protocol for the treatment of Oncol 16:E23–E29, 2018.
canine appendicular osteosarcoma following limb amputation, Aust 298. Kim C, Matsuyama A, Mutsaers AJ, et al.: Retrospective evaluation
Vet J 90:69–74, 2012. of toceranib (Palladia) treatment for canine metastatic appendicular
279. Frimberger AE, Chan CM, Moore AS: Canine osteosarcoma osteosarcoma, Can Vet J 58:1059–1064, 2017.
treated by post-amputation sequential accelerated doxorubicin 299. Wittenburg LA, Ptitsyn AA, Thamm DH: A systems biology
and carboplatin chemotherapy; 38 cases, J Am Anim Hosp Assoc approach to identify molecular pathways altered by HDAC inhibi-
52:149–156, 2016. tion in osteosarcoma, J Cell Biochem 113:773–783, 2012.
280. Skorupski KA, Uhl JM, Szivek A, et al.: Carboplatin versus alter- 300. Wittenburg LA, Gustafson DL, Thamm DH: Phase I pharmacoki-
nating carboplatin and doxorubicin for the adjuvant treatment of netic and pharmacodynamic evaluation of combined valproic acid/
canine appendicular osteosarcoma; a randomized, phase III trial, doxorubicin treatment in dogs with spontaneous cancer, Clin Can-
Vet Comp Oncol 14:81–87, 2016. cer Res 16:4832–4842, 2010.
281. Bracha S, Walshaw R, Danton T, et al.: Evaluation of toxicities from 301. Hershey AE, Kurzman ID, Forrest LJ, et al.: Inhalation chemo-
combined metronomic and maximal-tolerated dose chemotherapy in therapy for macroscopic primary or metastatic lung tumors; proof
dogs with osteosarcoma, J Small Anim Pract 55:369–374, 2014. of principle using dogs with spontaneously occurring tumors as a
282. Matsuyama A, Schott CR, Wood GA, et al.: Evaluation of metro- model, Clin Cancer Res 5:2653–2659, 1999.
nomic cyclophosphamide chemotherapy as maintenance treatment for 302. Rodriguez CO, Crabbs TA, Wilson DW, et al.: Aerosol gemcitabine;
dogs with appendicular osteosarcoma following limb amputation and preclinical safety and in vivo antitumor activity in osteosarcoma-
carboplatin chemotherapy, J Am Vet Med Assoc 252:1377–1383, 2018. bearing dogs, J Aerosol Med Pulm D 23:197–206, 2010.